JOSEPH A. AKERS - Corporate Board Profile

TITAN PHARMACEUTICALS INC

Filing Date	Source Excerpt
2015-07-20	Joseph A. Akers was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. Mr. Akers received a B.S. in marketing and an M.B.A. in finance from the University of California at Berkeley. Based on Mr. Aker's extensive management experience in the pharmaceutical industry, particularly in the areas of administration and finance, our Board believes that Mr. Akers has the appropriate set of skills to serve as a member of the Board.
2016-06-29	Joseph A. Akers (70) was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. He has served on our Board since November 2014. Based on Mr. Akers extensive management experience in the pharmaceutical industry, particularly in the areas of administration and finance, our Board believes that Mr. Akers has the appropriate set of skills to serve as a member of the Board.
2017-06-26	Joseph A. Akers was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007. Based on Mr. Akers’ extensive management experience in the pharmaceutical industry, particularly in the areas of administration and finance, our Board believes that Mr. Akers has the appropriate set of skills to serve as a member of the Board. The audit committee currently consists of Joseph A. Akers (chair), M. David MacFarlane and James R. McNab, Jr. The compensation committee currently consists of Scott A. Smith (chair), Joseph A. Akers and M. David MacFarlane. Joseph A. Akers 2016 Total Compensation $57,500.
2018-07-02	Joseph A. Akers was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007. The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 and currently consists of Joseph A. Akers (chair), M. David MacFarlane and James McNab, each of whom meets the independence requirements and standards currently established by the Nasdaq. The compensation committee currently consists of Scott Smith (chair), Joseph A. Akers and M. David MacFarlane, each of whom meets the independence requirements and standards currently established by Nasdaq. The following table summarizes compensation that our non-employee directors earned during 2017 for services as members of our Board. Joseph A. Akers earned $96,627 in total compensation.
2018-12-20	The following table summarizes compensation that our non-employee directors earned during 2018 for services as members of our Board. Joseph A. Akers Fees Earned or Paid in Cash ($): $57,500 Total ($): $57,500
2019-11-20	Joseph A. Akers (74) was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. ... The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (the “Exchange Act”) and currently consists of Joseph A. Akers (chair), M. David MacFarlane and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. In addition, the Board has determined that Mr. Akers is an “audit committee financial expert” and “independent” as defined under the relevant rules of the SEC and Nasdaq.
2020-01-31	Joseph A. Akers(3) Includes (i) 6,138 shares issuable upon exercise of outstanding options and (ii) 33,334 shares issuable upon exercise of outstanding warrants.
2020-05-22	Name and Address of Beneficial Owner(1) Joseph A. Akers(3)
2020-11-02	Joseph A. Akers(3) Includes (i) 6,138 shares issuable upon exercise of outstanding options and (ii) 33,334 shares issuable upon exercise of outstanding warrants.
2020-11-25	Joseph A. Akers (75) was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 and currently consists of Joseph A. Akers (chair), M. David MacFarlane, Ph.D. and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. In addition, the Board has determined that Mr. Akers is an “audit committee financial expert” and “independent” as defined under the relevant rules of the SEC and Nasdaq. The compensation committee currently consists of Joseph A. Akers, M. David MacFarlane, Ph.D. (chair) and Scott A. Smith, each of whom meets the independence requirements and standards currently established by Nasdaq. The nominating committee consists of Joseph A. Akers, M. David MacFarlane, Ph.D. and Scott A. Smith (chair), each of whom meets the independence requirements and standards currently established by Nasdaq. The following table summarizes compensation that our non-employee directors earned during 2019 for services as members of our Board. Joseph A. Akers earned $57,500.
2021-11-05	Joseph A. Akers (76) was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. ... The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (the “Exchange Act”) and currently consists of Joseph A. Akers (chair), M. David MacFarlane, Ph.D. and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. In addition, the Board has determined that Mr. Akers is an “audit committee financial expert” and “independent” as defined under the relevant rules of the SEC and Nasdaq.
2023-05-19	The audit committee currently consists of Joseph A. Akers, M. David MacFarlane, Ph.D., Matthew C. McMurdo, James R. McNab, Jr. and David Natan (chair)... The compensation committee currently consists of Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Ph.D., James R. McNab, Jr. and David Natan (chair)... The nominating and governance committee consists of Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Ph.D., and James R. McNab, Jr. (chair)... Joseph A. Akers 2022 compensation total $71,359.